ATE247652T1 - 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden - Google Patents

4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden

Info

Publication number
ATE247652T1
ATE247652T1 AT00919753T AT00919753T ATE247652T1 AT E247652 T1 ATE247652 T1 AT E247652T1 AT 00919753 T AT00919753 T AT 00919753T AT 00919753 T AT00919753 T AT 00919753T AT E247652 T1 ATE247652 T1 AT E247652T1
Authority
AT
Austria
Prior art keywords
compounds
gaba
receptors
receptor ligands
quinoline derivatives
Prior art date
Application number
AT00919753T
Other languages
English (en)
Inventor
Jun Yuan
George D Maynard
Alan Hutchison
Stanislaw Rachwal
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Application granted granted Critical
Publication of ATE247652T1 publication Critical patent/ATE247652T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • G01N33/9426GABA, i.e. gamma-amino-butyrate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00919753T 1999-03-29 2000-03-28 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden ATE247652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12692699P 1999-03-29 1999-03-29
PCT/US2000/008205 WO2000058303A1 (en) 1999-03-29 2000-03-28 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands

Publications (1)

Publication Number Publication Date
ATE247652T1 true ATE247652T1 (de) 2003-09-15

Family

ID=22427414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919753T ATE247652T1 (de) 1999-03-29 2000-03-28 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden

Country Status (8)

Country Link
US (2) US6413982B1 (de)
EP (1) EP1165542B1 (de)
JP (1) JP2002540203A (de)
AT (1) ATE247652T1 (de)
AU (2) AU4038000A (de)
CA (1) CA2368455A1 (de)
DE (1) DE60004654T2 (de)
WO (2) WO2000058313A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
CA2388593A1 (en) 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
RU2309154C9 (ru) 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
GB0226462D0 (en) * 2002-11-13 2002-12-18 Merck Sharp & Dohme Therapeutic agents
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
WO2005061462A2 (en) * 2003-12-19 2005-07-07 Neurogen Corporation Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators
WO2005066137A1 (en) * 2003-12-19 2005-07-21 Neurogen Corporation 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases
US20050277639A1 (en) * 2004-03-02 2005-12-15 Phil Skolnick 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2005099680A2 (en) 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
CA2565599C (en) * 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
MY146992A (en) * 2007-06-18 2012-10-15 Richter Gedeon Nyrt Sulfonyl-quinoline derivatives
EP2508177A1 (de) 2007-12-12 2012-10-10 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
US7863295B2 (en) * 2008-02-12 2011-01-04 Children's Medical Center Corporation Treatments for neuropathy
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
CA3186659A1 (en) * 2020-06-10 2021-12-16 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
SK282721B6 (sk) 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
WO1996020193A1 (en) 1994-12-23 1996-07-04 Smithkline Beecham Corporation Compounds and methods
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
GB9524137D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
BR9611820A (pt) 1995-11-24 1999-07-13 Smithkline Beecham Spa Derivados de quinolina
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
US5792766A (en) 1996-03-13 1998-08-11 Neurogen Corporation Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands
EP0983262B1 (de) 1997-05-23 2003-07-09 GlaxoSmithKline S.p.A. Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
US6228868B1 (en) * 1998-07-27 2001-05-08 Abbott Laboratories Oxazoline antiproliferative agents
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands

Also Published As

Publication number Publication date
WO2000058313A1 (en) 2000-10-05
AU4038000A (en) 2000-10-16
US20020198232A1 (en) 2002-12-26
WO2000058303A1 (en) 2000-10-05
DE60004654D1 (de) 2003-09-25
CA2368455A1 (en) 2000-10-05
EP1165542A1 (de) 2002-01-02
US6624175B2 (en) 2003-09-23
EP1165542B1 (de) 2003-08-20
US6413982B1 (en) 2002-07-02
AU4038600A (en) 2000-10-16
DE60004654T2 (de) 2004-06-24
JP2002540203A (ja) 2002-11-26
WO2000058303A9 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
ATE247652T1 (de) 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
AP1503A (en) Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
ATE347553T1 (de) Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
NO20070347L (no) Modulatorer av alfa7 nikotinske acetylkolinreseptorer og terapeutiske anvendelser
MXPA04000372A (es) Compuesto biciclicos de heteroarilo fusionados sustituidos con heteroarilo como ligandos del receptor gabaa.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
ATE304533T1 (de) Tetrahydrochinolinderivate als muscarinische agonisten
DE60309057D1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
DE60232029D1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
DE60309852D1 (de) Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
MA29643B1 (fr) Benzocycloheptapyridines comme inhibiteurs du recepteur tyrozine kinase met
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
DE60313898D1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
MXPA04000023A (es) Derivados de acido cicloalquilpirrol-3-carboxilico y derivados de acido heterocicloalquilpirrol-3-carboxilico como ligandos de receptor gabaa.
MA29694B1 (fr) Derives de l'imidazopyridine comme ligands du recepteur cannabinoide
DE602004011914D1 (de) Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165542

Country of ref document: EP

REN Ceased due to non-payment of the annual fee